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Sulfated glycosaminoglycans (GAG) are components of the bone marrow stem cell niche and to a minor extent of mature bone
tissue with important functions in regulating stem cell lineage commitment and differentiation. We anticipated that artificial
extracellular matrices (aECM) composed of collagen I and synthetically oversulfated GAG derivatives affect preferentially the
differentiation of osteoblast-precursor cells and early osteoblasts. A set of gradually sulfated chondroitin sulfate and hyaluronan
derivatives was used for the preparation of aECM. All these matrices were analysed with human bone marrow stromal cells to
identify the most potent aECM and to determine the influence of the degree and position of sulfate groups and the kind of
disaccharide units on the osteogenic differentiation. Oversulfated GAG derivatives with a sulfate group at the C-6 position of the
N-acetylglycosamine revealed the most pronounced proosteogenic effect as determined by tissue nonspecific alkaline phosphatase
activity and calcium deposition. A subset of the aECM was further analysed with different primary osteoblasts and cell lines
reflecting different maturation stages to test whether the effect of sulfated GAG derivatives depends on the maturation status of
the cells. It was shown that the proosteogenic effect of aECM was most prominent in early osteoblasts.
1. Introduction
Extracellular matrix (ECM) is an important component of
the stem cell niche influencing stem cell fate [1]. Bone
marrow stromal cells (BMSC) sense not only neighbouring
cells such as hematopoietic stem cells, sinusoidal endothelial
cells, or fat cells but also the chemical composition of
their microenvironment. In the bone marrow niche, the
BMSC are in contact with several collagen types, fibronectin,
and sulfated glycosaminoglycans (sGAG), mainly heparan
sulfate [2]. There is growing evidence from in vitro studies
on the importance of sGAG in facilitating the osteogenic
differentiation route of BMSC [3, 4]. Heparan sulfate was
identified as an important factor initiating embryonic stem
cells to exit from self-renewal and regulating their lineage
fate [5]. Kraushaar et al. [6] pointed out that embryonic
stem cell differentiation is accompanied by structural changes
of heparan sulfate, for example, by increasing degree of
sulfation of N-, 3-O-, and 6-O-position. Mature bone ECM
contains much less sGAG (less than 1% of bone dry weight)
than the ECM of bone marrow and consists predomi-
nantly of mineralized collagen [7, 8]. Synthetically sulfated
hyaluronan derivatives (sHA) and oversulfated chondroitin
sulfate derivatives (sCS) as components of artificial ECM
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(aECM) have been recently described to promote adhesion
and proliferation of dermal fibroblasts [9] and to influ-
ence osteoclastogenesis [10]. aECM with sHA derivatives
are known to enhance osteogenic differentiation of hBMSC
even in the absence of dexamethasone [11] which has been
described as an established supplement to induce osteogenic
differentiation in vitro [12].
In this study, a set of gradually sulfated hyaluronan and
chondroitin sulfate derivatives differing in the number and
the position of sulfate groups was used for the preparation
of aECM. The aECM were applied as a substrate for several
osteoblast precursor cells and cell lines derived from different
sources and origins.We hypothesized that the response to the
aECM will depend on the maturation state of the cell (line)s.
TNAP activity and calcium deposition were determined as
markers for osteogenic differentiation.
2. Materials and Methods
Unless otherwise mentioned, cell culture reagents were from
Biochrom KG (Berlin Germany); fetal calf serum was from
BioWest (via Th.Geyer, Hamburg, Germany); cell culture
plastic ware was from Greiner BioOne (Frickenhausen,
Germany) and Nunc (via Thermo Scientific, Langensel-
bold, Germany); and biochemical reagents were from Sigma
(Taufkirchen, Germany). Rat tail collagen I was from BD
Bioscience (Heidelberg, Germany) and chondroitin sulfate
(sCS1; bovine trachea) from Sigma.
2.1. Preparation and Characterisation of Artificial Extracellu-
lar Matrices (aECM). Table 1 lists the GAG derivatives which
were used for the preparation of the aECM. The synthesis
and characterization of (s)GAG derivatives were performed
as described earlier [9, 11, 13]. The preparation of the sulfated
HA derivative sHA1Δ6S was previously reported by Becher
et al. [14] and Schulz et al. [15]. aECM were prepared from
collagen I (col) and (s)GAG derivatives as described in [9,
11, 13]. Briefly, 1mg collagen I was dissolved in 1mL of ice
cold 10mM acetic acid and was mixed with an equal volume
of 1mg (s)GAG derivative/mL dissolved in ice cold double
concentrated fibrillogenesis buffer (50mM sodium dihydro-
genphosphate and 11mM potassium dihydrogenphosphate,
pH 7.4). 220𝜇L of the collagen I/(s)GAG derivative mixture
per cm2 was placed onto tissue culture polystyrene plates
(TCPS). Fibrillogenesis was performed overnight at 37∘C.
The resulting aECM were air-dried, washed two times with
1mL deionised, sterile water, and air-dried again. Before cell
culture experiments aECM were rinsed with sterile PBS for
1 h at 37∘C.
2.2. Isolation of Primary Osteoblast-Precursor Cells/Premature
Osteoblasts and Cultivation of Cells. Human bone marrow
stromal cells (hBMSC) were isolated from bone marrow
aspirates, obtained from Caucasian donors (average age
32 ± 7 yrs., male and female donors), at the Bone Marrow
Transplantation Center of the University Hospital Dresden,
and were characterized as described in [16]. The donors were
informed about the procedures and gave their full consent.
Table 1: Characteristics of the GAG derivatives.
Sample DSS
a MW
b
[g/mol] PD
c
sCS1 Chondroitin sulfate 1 17,900 1.4
sCS2 Sulfated chondroitin sulfate 2 23,200 1.5
sCS3 Sulfated chondroitin sulfate 3 19,900 1.5
HA Hyaluronan 0 1,17 × 106 4.8
sHA1Δ4S Sulfated hyaluronan 1 26,400 2.0
sHA1Δ6S Sulfated hyaluronan 1 42,600 2.0
sHA2 Sulfated hyaluronan 2 26,400 1.8
sHA3 Sulfated hyaluronan 3 47,800 1.7
aDSS: degree of sulfation (average number of sulfate groups per disaccharide
repeating unit).
bMW: weight-average molecular weight determined by gel permeation
chromatography (GPC) using laser light scattering (LLS) detection.
cPD: polydispersity index, determined from the molecular weight distri-
bution calculated from the number-average and weight average molecular
weights obtained by GPC with refraction index (RI) detection.
The study was approved by the Local Ethics Commission
(ethic vote No. EK114042009). Four hBMSC preparations
were chosen for the experiments according to prior char-
acterization of their osteogenic differentiation capacity and
according to the characteristic “similar basal TNAP activity
in passage 1.” hBMSC preparations of individual donors were
not pooled. The cells were used in passages 2–4.
For isolation of primary rat osteoblasts/osteoblast-
precursors, NIH guidelines for the care and use of laboratory
animals were considered. Rat calvarial osteoblasts (rCaOB)
were isolated from new-born Wistar rats and characterized
as described [17]. Rat bone marrow stromal cells (hBMSC)
were isolated from femora and tibiae of adult Wistar rats
(2-3-month old). The bones were dissected and the bone
marrow was flushed three times with medium containing
10% HI-FCS and antibiotics. The cell suspension was
filtered through a 40 𝜇m strainer, pelleted, and treated
for 4min. with ACK solution (155mM NH
4
Cl, 10mM
KHCO
3
, 110mM Na
2
EDTA, pH 7.4) to remove erythrocytes.
Subsequently, cells were resuspended in medium and
plated onto tissue culture polystyrene (TCPS) plates. The
osteoblast phenotype was confirmed by determination of
tissue nonspecific alkaline phosphatase (TNAP) activity and
calcium phosphate deposits. The cell lines MG-63 (CRL-
1427), SaOS-2 (HTB-85), and MC3T3-E1 clone 4 (CRL-2593)
were obtained from ATCC (American Tissue & Cell Culture
via LGC Standards GmbH, Wesel, Germany) and cultured
according to supplier’s recommendations. MLO-Y4 cell line
was described in detail by Kato et al. [18] and was a kind gift
from Lynda Bonewald (Kansas City, USA).
Cell characteristics, plating density, and media used for
cell expansion are given in Table 2. In order to have the
different cell (line)s at day 4 after plating in the same state of
subconfluency, hBMSC were plated with deviant cell density
considering that the cells are larger in size [19]. Primary
cells were used from the second to fourth passage. All media
contained 2mMglutamine and 10,000 IE penicillin/10,000𝜇g
streptomycin/mL. For the experiments, cells were plated onto
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Table 2: Cell culture conditions.
Cells Species Expansion medium Seeding density
[cells/cm2] Source Characteristics
hBMSC Human DMEM/10% HI-FCS 7,000 Iliac crest/bone marrow Primary cells Osteoblast-precursors
MG-63 Human DMEM/10% HI-FCS 12,500 Long bones/osteosarcoma Cell line Premature osteoblasts
SaOS-2 Human McCoys5A/15% HI-FCS 12,500 Long bones/osteosarcoma Cell line Mature osteoblasts
rCaOB Rat DMEM/10% HI-FCS 12,500 Skull/calvariae Primary cells Premature osteoblasts
rBMSC Rat DMEM/10% HI-FCS 12,500 Long bones/bone marrow Primary cells Osteoblast-precursors
MC3T3-E1 Mouse 𝛼-MEM/10% HI-FCS 12,500 Skull/calvariae Cell line Premature osteoblasts
MLO-Y4 Mouse 𝛼-MEM/10% HI-FCS 12,500 Long bones/femora, tibiae Cell line Senescent osteoblasts(osteocytes)
TCPS or aECM-coated TCPS in medium as listed in Table 2
(=basal medium, BM). At day 4 after plating cells were
cultured in BM, in BM supplemented with 10mM 𝛽-glycerol
phosphate and 300𝜇M ascorbate (=osteogenic medium,
OM), and in OM supplemented with 10 nM dexamethasone
(dex.) (=OM/D). At day 11 after plating the activity of TNAP
was determined, and at day 22 after plating the amount of
deposited calcium was quantified.
2.3. Determination of TNAP Activity. TNAP activity was
determined in cell lysates (lysis buffer: 1.5M Tris-HCl (pH
10), 1mM ZnCl
2
, 1 mMMgCl
2,
and 1% Triton X-100) with p-
nitrophenyl phosphate as a substrate as described previously
[20]. TNAP activity was calculated from a linear calibration
curve (𝑟 = 0.9979) prepared with p-nitrophenol. Specific
TNAP activity is given inmU/mg protein. Protein concentra-
tion of the lysate was determined by Rotiquant assay (Roth
GmbH, Karlsruhe, Germany) and calculated from a linear
calibration curve (𝑟 = 0.9967) obtained with bovine serum
albumin.
2.4. Determination of Calcium Deposition. Calcium deposi-
tionwas quantifiedwith the calciumkit (GreinerDiagnostics,
Bahlingen, Germany) as previously described [11]. Cell layers
were washed with PBS, dried, and incubated with 0.5M HCl
at 4∘C for 24 h. Calcium content in the lysates was quantified
photometrically with cresolphthalein complexone at 570 nm
from a linear calibration curve (𝑟 = 0.9978) prepared with
calcium chloride. Calcium content is given in 𝜇mol/cm2
culture area.
2.5. Morphology of hBMSC on aECM. At day 11 after plating
on the different aECM, F-actin arrangement was monitored
by fluorescence staining. The cells were washed gently with
PBS and incubated with 4% paraformaldehyde (w/v) (Sigma,
Taufkirchen, Germany) in PBS for 10min. After permeabi-
lization with 0.1% Triton X-100 (Sigma) in PBS for 20min,
nonspecific binding sites were blocked with 1% bovine serum
albumin (w/v) (Sigma) in PBS containing 0.05% Tween-
20 (Sigma). The cells were incubated with 5U AlexaFluor-
488 phalloidin/mL (Invitrogen, Karlsruhe, Germany) of PBS
containing 1% bovine serum albumin and 0.05% Tween-
20 at 25∘C for 1 h. Subsequently 0.2 𝜇g 4󸀠,6-diamidino-2-
phenylindole (DAPI)/mL (Sigma) PBS for nuclei staining
was applied for 15min at 25∘C. Afterwards, the cells were
embedded in Mowiol 4–88 (Sigma) and visualized using an
AxioPhot fluorescence microscope (Carl Zeiss, Oberkochen,
Germany). For detection of the fluorescence, the follow-
ing filters were used: excitation 450–490 nm and emission
515–565 nm for AlexaFluor-488, an excitation 365 nm and
emission 420 nm for DAPI. Digital images were obtained
with an AxioCam MRm camera (Carl Zeiss) by using Axio-
Vision software release 4.6 (Carl Zeiss).
2.6. Statistical Analysis. Each experiment was performed
with nonpooled cells from four different donors (in the
case of primary cells: hBMSC, rCaOB, rBMSC) or four
independent cell cultures (in the case of cell lines: MG-63,
SaOS-2, MC3T3-E1, and MLO-Y4) each in triplicate. The
results are presented as mean ± standard error of the mean
(SEM). Statistical significance was analyzed with GraphPad
Prism 5.04 software (Statcon, Witzenhausen, Germany) by
one-way ANOVA (Figures 2 and 3) and two-way ANOVA
analysis (Figure 4, Table 3) with Bonferroni’s posttest.
3. Results and Discussion
3.1. Effect of aECM with Gradually Sulfated GAG Derivatives
on TNAP Activity, Calcium Deposition, and Morphology of
hBMSC. Gradually sulfated GAG derivatives were synthe-
sized using natural chondroitin sulfate (C4S = CSA = sCS1)
(Figure 1(a)) and natural hyaluronan (Figure 1(b)) as educts.
These derivatives were used to prepare collagen I matrices
with about 2–7% (w/w) of GAG (for characteristics see [11,
13]). Using aECMwith gradually sulfated GAG derivatives as
a substrate for hBMSC, we addressed the effects of the degree
of sulfation, the position of sulfate group(s), and the kind
of disaccharide unit (HA: glucuronic acid (GlcA)-N-acetyl-
glucosamine (NAcGlc); CS: GlcA-N-acetyl-galactosamine
(NAc-Gal)) on TNAP activity and calcium deposition. aECM
composed of col were used as a reference. hBMSCwere plated
in BM onto aECM, differentiated in OM/D from day 4, and
analysed at day 11 after plating for TNAP activity and at
day 22 after plating for calcium deposition. Both parameters
were determined as indicators of osteogenic differentiation
[12]. aECM containing sCS2, sCS3, sHA1Δ4S, sHA2, and
sHA3 caused a significant increase of TNAP activity by
about threefold in comparison to col-aECM (Figure 2(a))
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whereas aECM containing sCS1, hyaluronan, and sHA1Δ6S
did not alter TNAP activity. Once sufficient phosphate was
released by TNAP from the in vitro-substrate 𝛽-glycerol
phosphate (component of OM/D) the mineralisation took
place. The elevated calcium deposition around hBMSC on
aECM containing sCS2, sCS3, sHA1Δ4S, sHA2, and sHA3
(Figure 2(b)) correlated with increased TNAP activity. The
different aECMdid not cause appreciable changes of cellmor-
phology as assessed by F-actin staining (Figure 2(c)). A well-
organized, dense F-actin cytoskeleton forming strong fibres
was seen in hBMSC on col, col/sCS1, col/HA, col/sHA1Δ4S,
and col/sHA1Δ6S. On col/sCS2, col/sCS2, col/sHA2, and
col/sHA3, the F-actin fibres looked slightly tender; neverthe-
less, they formed also a tight cytoskeletal network.
Sulfated GAG derivatives per se and as a component of
aECM were shown to enhance osteogenic differentiation of
hBMSC [11, 20]; however, it was not really clear whether
the effect was dependent on the number and/or position
of sulfate groups and was influenced by the kind of disac-
charide unit. Here we demonstrated with hBMSC that the
effect of col/sGAG-aECM on TNAP activity and calcium
deposition was independent of the kind of disaccharide units
(GlcA-GlcNac or GlcA-GalNAc) and the absolute number
of sulfated groups. This effect was seen to the same extent
with sulfated chondroitin sulfate derivatives sCS2 and sCS3
and all sulfated hyaluronan derivatives (besides sHA1Δ6S),
respectively. An increasing degree of sulfation (sCS3 versus
sCS2; sHA2 and sHA3 versus sHA1Δ4S) did not significantly
alter the effect on TNAP activity and calcium deposition.
Other than the number of sulfate groups their position seems
to be important: sGAG derivatives without sulfate group in
C-6 position but with a sulfate group at C-4 position of
the N-acetyl-glucosamine such as the native chondroitin-4-
sulfate (sCS1) and the sHA1Δ6S derivative did not increase
TNAP activity and calcium deposition, suggesting that the
sulfation of the hydroxyl group at C-6 position of the N-
acetyl-glucosamine is necessary for the proosteogenic effect
of sGAG. For a further proof of this hypothesis, the use
of chondroitin-6-sulfate as a component of aECM would
be helpful. Sufficiently pure chondroitin-6-sulfate, however,
was not available; the commercially chondroitin-6-sulfate
consists to more than the half of chondroitin-4-sulfate [11].
3.2. Influence of aECM on Osteoblast-Precursor Cells, Prema-
ture and Mature Osteoblasts. Various primary cells and cell
lines of human, rat, andmouse originwere used to investigate
whether the effect of aECM on osteogenic differentiation is
restricted solely to human BMSC or whether it is obtained
also for cells of other species. To see if the response to
the aECM depends on the maturation stage of the cells,
osteoblast-precursor cells, premature and mature osteoblasts
of human, rat and mouse origin were subjected to col/sCS3-
and col/sHA3-aECM in comparison to col-, col/sCS1-, and
col/HA-aECM.The in vitro experimentswere performedwith
human and rat bone marrow-derived stromal cells (BMSC)
reflecting osteoblast-precursor cells, with human MG-63 cell
line, primary rat calvaria osteoblasts (rCaOB) and mouse
MC3T3-E1 cell line reflecting early premature osteoblasts,
andwith humanSaOS-2 cell line andmouseMLO-Y4 cell line
reflecting late mature osteoblasts, respectively. To evaluate
whether 𝛽-glycerol phosphate and ascorbate are sufficient
supplements for the induction of osteogenic differentiation or
whether dexamethasone ismandatory, the cells were cultured
on TCPS in basal medium (BM), osteogenic medium (OM)
containing 𝛽-glycerol phosphate and ascorbate, and OM/D
(OM supplemented with dexamethasone), respectively, and
analysed for TNAP activity at day 11 (Figure 3). Dexametha-
sone (OM/D) was essential to induce TNAP activity in both
human BMSC and MG-63 (Figure 3(a)) but not in rBMSC
and rCaOB (Figure 3(b)). 𝛽-Glycerol phosphate and ascor-
bate (OM)were sufficient for human SaOS-2 to induce TNAP
activity; withOM/Dno further increase of TNAP activity was
seen (Figure 3(a)). In rCaOB, an increase of TNAP activity
was seenwithOM,whereas in the presence of dexamethasone
TNAP remained at the level of BM (Figure 3(b)). TNAP
activity of rBMSC (Figure 3(b)) and MC3T3-E1 (Figure 3(c))
was not dependent on medium supplements. In MLO-
Y4, dexamethasone caused a significant decrease of TNAP
activity (Figure 3(c)).
Cells were plated on col-aECM as a reference and on
col-aECM containing sCS1, sCS3, HA, and sHA3. They were
cultured in BM, OM, and OM/D and analysed for TNAP
activity at day 11 (Figure 4). aECM with sCS3 and sHA3
induced an increase of TNAP activity in hBMSC, MG-63,
rCaOB, and rBMSC; this effect was not dependent on the
addition of osteogenic supplements and always present in
BM (Figures 4(a) and 4(b)). TNAP activity of SaOS-2 was
rather negatively influenced by all aECM compared to TCPS
(dotted line = 100%; Figure 4(a)); in comparison to BM,
the effect was more pronounced when SaOS-2 were cultured
in OM/D and OM. In MC3T3-E1, the contact to sCS3- and
sHA3-containing aECM caused a decrease of TNAP activity;
the other aECM did not alter TNAP activity (Figure 4(c)).
TNAP activity of MLO-Y4 was higher in cells on col/sCS1-
aECM than in cells on col-aECM (Figure 4(c)).
The results of calcium determination on aECM at day
22 are summarized in Table 3. In all cell (line)s, a marked
calcium deposition was only seen when the cells were
cultured inOMandOM/D (both containing𝛽-glycerol phos-
phate). In comparison to col-aECM, aECM with sCS3 and
sHA3 induced a significant increase of calcium deposition
in hBMSC, MG-63, rCaOB, and rBMSC. The decrease of
calciumdeposition inMC3T3-E1 on col/sCS3- and col/sHA3-
aECM correlated to the effect of these aECM on TNAP activ-
ity. With SaOS-2 cells no significant differences in calcium
deposition between the different aECMwere found in OM/D
and OM. According to the effect on TNAP activity, col/sCS1-
aECM caused in MLO-Y4 cells in OM/D a significant higher
calcium deposition in comparison to col-aECM.
The results indicate that primary osteoblasts-precursor
cells as well as premature osteoblasts (BMSC, MG-63, and
early osteoblasts isolated from calvariae of newborn rats) are
responsive to aECM with oversulfated GAG derivatives such
as col/sCS3 and col/sHA3. BMSC are multipotent precursor
cells which can be differentiated into fibrogenic, myogenic,
neuronal, osteogenic, chondrogenic, and adipogenic lineage;
the signals driving them into a particular differentiation
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Figure 1: Chemical structure of sGAG derivatives. The chemical structure of chondroitin sulfate derivatives (a) and hyaluronan derivatives
(b) and the most putative pattern of substituents as determined by [13C] nuclear magnetic resonance analysis are given.
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Figure 2: Influence of aECM on TNAP activity, calcium deposition, and morphology of hBMSC. 7,000 hBMSC were plated in BM on
aECM. At day 4 after plating, BM was replaced with OM/D. At day 11 after plating, TNAP activity was determined in cell lysates with p-
nitrophenylphosphate as a substrate (a). The released p-nitrophenolate was measured photometrically at 405 nm. TNAP activity in mU/mL
was normalized to protein concentration in mg/mL determined with Rotiquant assay. At day 22 after plating, calcium deposition was
quantified with cresolphthalein complexone at 570 nm (b). Significant differences of col/sGAG-aECM versus col-aECM were calculated by
one-way ANOVA analysis and indicated with c (𝑃 < 0.001), 𝑛 = 4. (c) At day 11 after plating, cells were stained for F-actin fibres with
Alexa488-phallodin (green fluorescence) and for nuclei with DAPI (blue fluorescence), scale bar = 50 𝜇m.
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Figure 3: Influence of medium supplements on TNAP activity of osteoblast-precursor cells, premature and mature osteoblasts. Various
human (hBMSC, MG-63, SaOS-2) (a), rat (rCaOB, rBMSC) (b), and mouse cell (line)s (MC3T3-E1, MLO-Y4) (c) were plated in BM on
TCPS. At day 4 after plating cells were cultured either in BM, OM, or OM/D. At day 11 after plating, TNAP activity was determined in cell
lysates with p-nitrophenylphosphate as a substrate. The released p-nitrophenolate was measured photometrically at 405 nm. TNAP activity
in mU/mL was normalized to protein concentration in mg/mL determined with Rotiquant assay. Significant differences were calculated by
one-way ANOVA analysis and indicated with a (𝑃 < 0.05), b (𝑃 < 0.01) and c (𝑃 < 0.001), 𝑛 = 4.
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Figure 4: Influence of aECM on TNAP activity of osteoblast-precursor cells, premature and mature osteoblasts. Various human (hBMSC,
MG-63, SaOS-2) (a), rat (rCaOB, rBMSC) (b), and mouse cell (line)s (MC3T3-E1, MLO-Y4) (c) were plated in BM on aECM composed of
collagen I and sCS1, sCS3, HA, and sHA3, respectively. At day 4 after plating cells were cultured either in BM, OM, or OM/D. At day 11 after
plating, TNAP activity was determined in cell lysates with p-nitrophenylphosphate as a substrate.The released p-nitrophenolatewasmeasured
photometrically at 405 nm. TNAP activity in mU/mL was normalized to protein concentration in mg/mL determined with Rotiquant assay.
Data are presented as % of TCPS values in the corresponding cell culture medium. Significant differences of OM/D, OM, and BM on (s) GAG
versus col-aECM were calculated by two-way ANOVA and indicated with a (𝑃 < 0.05), b (𝑃 < 0.01), and c (𝑃 < 0.001), 𝑛 = 4.
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Table 3: Influence of aECM on mineralisation of osteoblast-precursor cells, premature and mature osteoblasts.
aECM
col col/sCS1 col/sCS3 col/HA col/sHA3
hBMSC
OM/D 0.540 ± 0.066 0.778 ± 0.164 1.563 ± 0.086c 0.538 ± 0.082 1.405 ± 0.116b
OM 0.286 ± 0.068 0.355 ± 0.098 0.734 ± 0.135b 0.186 ± 0.049 0.724 ± 0.130b
BM 0.093 ± 0.004 0.044 ± 0.007 0.070 ± 0.007 0.074 ± 0.002 0.096 ± 0.009
MG-63
OM/D 0.043 ± 0.001 0.040 ± 0.002 0.083 ± 0.002c 0.027 ± 0.002 0.080 ± 0.003c
OM 0.019 ± 0.002 0.014 ± 0.001 0.037 ± 0.003c 0.012 ± 0.001 0.031 ± 0.002c
BM 0.003 ± 0.002 0.001 ± 0.001 0.007 ± 0.002 0.009 ± 0.001 0.005 ± 0.003
SaOS-2
OM/D 6.584 ± 0.510 6.360 ± 0.322 7.766 ± 0.964 6.982 ± 0.689 8.495 ± 1.550
OM 6.865 ± 0.639 7.652 ± 0.519 8.504 ± 0.727 7.059 ± 0.393 8.466 ± 1.515
BM 0.058 ± 0.010 0.050 ± 0.058 0.059 ± 0.029 0.068 ± 0.055 0.035 ± 0.011
rCaOB
OM/D 4.408 ± 0.439 5.323 ± 0.526 11.09 ± 1.401c 3.937 ± 0.123 8.995 ± 0.961c
OM 6.552 ± 0.230 6.883 ± 0.244 15.70 ± 1.730c 5.135 ± 0.122 12.86 ± 0.981b
BM 0.075 ± 0.079 0.027 ± 0.006 0.048 ± 0.022 0.003 ± 0.005 0.014 ± 0.003
rBMSC
OM/D 1.625 ± 0.122 1.542 ± 0.129 3.296 ± 0.598c 1.444 ± 0.104 3.521 ± 0.311c
OM 1.559 ± 0.138 1.478 ± 0.086 3.553 ± 0.087c 1.325 ± 0.088 2.931 ± 0.240b
BM 0.009 ± 0.002 0.017 ± 0.005 0.030 ± 0.020 0.021 ± 0.010 0.010 ± 0.002
MC3T3-E1
OM/D 0.288 ± 0.080 0.352 ± 0.101 0.200 ± 0.026a 0.384 ± 0.082 0.090 ± 0.031b
OM 0.384 ± 0.082 0.376 ± 0.098 0.062 ± 0.005b 0.279 ± 0022 0.044 ± 0.003c
BM 0.005 ± 0.002 0.011 ± 0.005 0.006 ± 0.002 0.008 ± 0.003 0.005 ± 0.001
MLO-Y4
OM/D 2.359 ± 0.064 7.462 ± 2.161c 3.045 ± 0.423 3.436 ± 0.126 1.633 ± 0.132
OM 3.436 ± 0.126 7.849 ± 1.348 5.271 ± 0.371 3.783 ± 0.108 4.271 ± 0.108
BM 0.084 ± 0.006 0.028 ± 0.007 0.050 ± 0.014 0.048 ± 0.009 0.009 ± 0.007
Calcium amount [𝜇mol/cm2] given as mean ± SEM; significant differences of OM/D, OM, and BM on (s) GAG versus col-aECM were calculated by two-way
ANOVA and indicated with a(𝑃 < 0.05), b(𝑃 < 0.01), and c(𝑃 < 0.001), 𝑛 = 4.
route come from intrinsic genetic programming, diverse
soluble mediators, and the ECM. [21, 22]. Both MG-63 and
SaOS-2 are human osteosarcoma-derived cell lines; MG-
63 cells are referred to as premature osteoblasts; SaOS-
2 cells are characterized as mature osteoblasts [23–26]. In
contrast to MG-63, SaOS-2 cells did not respond to aECM
with high-sulfated GAG derivatives; no differences in TNAP
activity and calcium deposition were determined on all used
aECM. TNAP activity and calcium deposition of SaOS-2
was increased with all aECM in the presence of osteogenic
supplements (OM and OM/D). Both mouse MC3T3-E1
which are premature osteoblasts and MLO-Y4 which are
senescent osteoblasts did not response on aECM with high-
sulfated GAG derivatives. For MC3T3-E1 it was reported that
a natural oversulfated chondroitin sulfate derivative, isolated
from squid cartilage and consisting of GlcA 1→ 3 GalNAc
(C4-sulfate and C6-sulfate) disaccharide units, enhanced
the deposition of collagen and calcium phosphate [27]. In
contrast, our studies showed that aECM with high-sulfated
GAG derivatives (col/sCS3, col/sHA3) caused in MC3T3-
E1 a decrease of TNAP activity compared to col-aECM.
Reasonably this cell line share some but not all of features
of primary osteoblasts [28]. The osteocyte cell line MLO-
Y4 responded in OM/D—unlike the other osteoblasts—to
col/sCS1 with a significant increase of TNAP activity and
calcium deposition compared to col-aECM. MLO-Y4 cells
reflect the most mature late osteoblast phenotype used in this
study [29, 30]. Late osteoblasts/osteocytes derive from active
osteoblasts which had synthesized new bone matrix and
become incorporated therein [31]. Bone matrix maturation
is associated with altered GAG composition switching from
heparan sulfate-proteoglycans which are mainly responsible
for interaction with mediator proteins to chondroitin sulfate-
proteoglycans which are less potent in mediator binding
but support calcium accumulation [32, 33]. In adult bone
matrix, chondroitin-4-sulfate (=sCS1)was seen to be themost
abundant GAG [34]. The results of this study suggest that
synthetically sulfated GAG derivatives could partially reflect
the bone marrow environment and its influence on early
osteogenic differentiation.
4. Conclusion
Artificial ECMwith collagen I and oversulfated GAG deriva-
tives provide a cellular microenvironment which facilitates
the osteogenic differentiation preferentially of osteoblast-
precursor cells and early osteoblasts.The sulfate group in C-6
position of theN-acetyl- glucosamine seems to bemandatory
for the proosteogenic effect of sulfated GAG derivatives.
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and MG-63 revealed a pronounced osteogenic differentia-
tion on aECM with oversulfated GAG derivatives even in
the absence of dexamethasone. The strong osteoinductive
effect of aECM with oversulfated GAG derivatives (partially
independent on dexamethasone) makes them an interesting
tool for tissue engineering approaches.They are a structurally
well-characterised alternative to natural GAG to address the
effects of sulfated GAG on early osteogenic differentiation to
a defined GAG structure.
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